Skip to main content
. 2020 Feb 17;22(8):1162–1172. doi: 10.1093/neuonc/noaa033

Fig. 4.

Fig. 4

RTK I tumors show worse survival and similar to MES tumors lack of benefit from MGMT promoter methylation in NOA-08 patients. (A) OS of patients in the biomarker cohort according to classifier assignment. OS of patients according to MGMT promoter methylation status with (B) mesenchymal, (C) RTK I, and (D) RTK II classifier assignment.